Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Malignant Ascites 1

Interventions

pembrolizumab 222Carboplatin 215Cisplatin 203Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 114Cyclophosphamide 102Pemetrexed 100Dexamethasone 100Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 94Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 68durvalumab 65Lenalidomide 64Radiation 62atezolizumab 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Paracentesis × 1 year × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡